NasdaqCM - Delayed Quote • USD
Heron Therapeutics, Inc. (HRTX)
At close: April 24 at 4:00 PM EDT
Pre-Market: 8:54 AM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 3 | 4 |
| Avg. Estimate | -0.09 | -0.07 | -0.45 | -1.77 |
| Low Estimate | -0.11 | -0.09 | -0.79 | -6 |
| High Estimate | -0.07 | -0.05 | -0.2 | -0.02 |
| Year Ago EPS | -0.27 | -0.35 | -0.8 | -0.45 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 3 | 3 |
| Avg. Estimate | 32.8M | 34.37M | 145.93M | 175.5M |
| Low Estimate | 30.9M | 32.3M | 138M | 171.2M |
| High Estimate | 34.4M | 37.1M | 151.3M | 180.3M |
| Year Ago Sales | 29.61M | 31.76M | 127.04M | 145.93M |
| Sales Growth (year/est) | 10.80% | 8.20% | 14.90% | 20.30% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.2 | -0.23 | -0.29 | -0.16 |
| EPS Actual | -0.27 | -0.35 | -0.17 | -0.07 |
| Difference | -0.07 | -0.12 | 0.12 | 0.09 |
| Surprise % | -35.00% | -52.20% | 41.40% | 56.20% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.09 | -0.07 | -0.45 | -1.77 |
| 7 Days Ago | -0.09 | -0.07 | -0.45 | -0.36 |
| 30 Days Ago | -0.09 | -0.07 | -0.45 | -0.36 |
| 60 Days Ago | -0.11 | -0.09 | -0.43 | -0.22 |
| 90 Days Ago | -0.09 | -0.07 | -0.37 | -0.16 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | HRTX | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 66.70% | -- | -- | 1.50% |
| Next Qtr. | 80.00% | -- | -- | 11.40% |
| Current Year | 43.80% | -- | -- | 5.20% |
| Next Year | -293.30% | -- | -- | 13.40% |
| Next 5 Years (per annum) | 47.50% | -- | -- | 11.09% |
| Past 5 Years (per annum) | -43.36% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Initiated | Capital One: Overweight | 4/23/2024 |
| Reiterates | Needham: Buy to Buy | 4/11/2024 |
| Maintains | Needham: Buy to Buy | 3/13/2024 |
| Maintains | Needham: Buy to Buy | 11/15/2023 |
| Reiterates | Needham: Buy to Buy | 8/15/2023 |
| Maintains | Needham: Buy to Buy | 7/25/2023 |
Related Tickers
ARDX Ardelyx, Inc.
6.43
+0.63%
ADAP Adaptimmune Therapeutics plc
1.0800
-5.26%
KPTI Karyopharm Therapeutics Inc.
1.0900
0.00%
MREO Mereo BioPharma Group plc
2.7800
0.00%
GTHX G1 Therapeutics, Inc.
3.9900
-4.77%
DAWN Day One Biopharmaceuticals, Inc.
15.19
-8.71%
ABEO Abeona Therapeutics Inc.
3.1700
-7.04%
MCRB Seres Therapeutics, Inc.
0.7295
-4.01%
XFOR X4 Pharmaceuticals, Inc.
1.2900
+4.88%
OCUL Ocular Therapeutix, Inc.
4.6450
-7.10%